Atlas Trials

A Single Dose Study of the Safety, Pharmacokinetics and Pharmacodynamics of CDX-0159 in Patients With Cold Contact Urticaria, Symptomatic Dermographism, or Cholinergic Urticaria

Clinical trial NCT04548869 · COMPLETED

Trial details

NCT number
NCT04548869
Sponsor
Celldex Therapeutics
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Cold UrticariaCold Contact UrticariaSymptomatic DermographismSymptomatic DermatographismCholinergic Urticaria
Start date
2020-11-24
Primary completion
2022-12-16
Enrollment
41

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.